# Prevalence and correlates of food insecurity in community-based individuals with severe mental illness receiving long-acting injectable antipsychotic treatment

Scott B. Teasdale<sup>1\*</sup>, Rachel Morell<sup>1</sup>, Julia M. Lappin<sup>1</sup>, Jackie Curtis<sup>1,2</sup>, Andrew Watkins<sup>2,3</sup> and Philip B. Ward<sup>1,4</sup>

 <sup>1</sup>School of Psychiatry, University of New South Wales, Kensington 2033, Australia
 <sup>2</sup>Keeping the Body in Mind Program, South Eastern Sydney Local Health District, Bondi Junction 2022, Australia
 <sup>3</sup>Faculty of Health, University of Technology Sydney, Ultimo 2007, Australia
 <sup>4</sup>Schizophrenia Research Unit, South Western Sydney Local Health District and Ingham Institute of Applied Medical Research, Liverpool 2170, Australia

(Submitted 4 December 2019 - Final revision received 7 March 2020 - Accepted 18 March 2020 - First published online 1 April 2020)

#### Abstract

People with severe mental illness (SMI) have numerous risk factors that may predispose them to food insecurity (FI); however, the prevalence of FI and its effects on health are under-researched in this population. The present study aimed to describe the prevalence of FI and its relationship to lifestyle factors in people with SMI. This cross-sectional study recruited people with SMI receiving long-acting injectable (LAI) antipsychotic medication from community services at three sites in Sydney, Australia. Assessments were completed on physical health and lifestyle factors.  $\chi^2$  Tests, independent-samples *t* tests and binary logistic regression analyses were calculated to examine relationships between lifestyle factors and FI. In total, 233 people completed the assessments: 154 were males (66 %), mean age 44-8 (sp 12-7) years, and the majority (70 %) had a diagnosis of schizophrenia. FI was present in 104 participants (45 %). People with FI were less likely to consume fruits (OR 0-42, 95 % CI 0-24, 0-74, *P* = 0.003), vegetables (OR 0-39, 95 % CI 0-22, 0-69, *P* = 0.001) and protein-based foods (OR 0-45, 95 % CI 0-25, 0-83, *P* = 0.011) at least once daily, engaged in less moderate to vigorous physical activity (min) (OR 0.997, 95 % CI 0.993, 1.000, *P* = 0.044), and were more likely to smoke (OR 1-89, 95 % CI 1-08, 3-32, *P* = 0.026). FI is highly prevalent among people with SMI receiving LAI antipsychotic medications. Food-insecure people with SMI engage in less healthy lifestyle behaviours, increasing the risk of future non-communicable disease.

Key words: Food insecurity: Diet: Psychosis: Schizophrenia: Antipsychotic treatment

Food security, described as the consistent and assured access to and availability of safe sufficient food to support nutritional adequacy and a healthy life, is deemed a right for all humans<sup>(1)</sup>. In 2018, the WHO estimated that 11 % of people worldwide were undernourished and 10 % of people worldwide were experiencing severe food insecurity (FI), resulting in a call for action<sup>(2)</sup>. In Australia, rates of FI are estimated to be between 5 and 13 %<sup>(3–5)</sup>. A range of factors influence the level of food security including income, employment, ethnicity and disability<sup>(6)</sup>. Furthermore, food supply is affected by location and food availability, as well as by price, quality and variety<sup>(7,8)</sup>. FI develops when ongoing access and availability to food are limited or uncertain, with the impaired ability to acquire and use nutritious food in socially acceptable and safe ways<sup>(8,9)</sup>. The rising cost of food, particularly nutritious foods, increased cost of living and lower household incomes all contribute to and perpetuate  $FI^{(8,10)}$ .

In Australia, socially disadvantaged groups have been shown to have a higher prevalence of FI<sup>(8,11)</sup>. Such population groups include low-income households, rural/remote areas, indigenous, homeless, disabled, aged and migrant populations<sup>(10–12)</sup>. As these groups are highly associated with a lower socioeconomic status, food purchasing is often perceived as a discretionary expense relative to other living necessities<sup>(7,12)</sup>. A reduction in diet quality commonly follows with the overconsumption of energy-dense, non-nutritious foods, and lower intake of core foods such as fruits and vegetables, and important nutrients including fibre<sup>(13,14)</sup>. This increases the risk for obesity and diet-related disease, such as type II diabetes, heart disease and stroke<sup>(7,9,10)</sup>.

Abbreviations: FI, food insecurity; LAI, long-acting injectable; MVPA, moderate-to-vigorous physical activity; SMI, severe mental illness.

<sup>\*</sup> Corresponding author: Dr Scott B. Teasdale, fax +61 2 9387 1070, email scott.teasdale@unswalumni.com

https://doi.org/10.1017/S0007114520001191 Published online by Cambridge University Press

FI is known to be associated with poorer mental health status and increased suicidality<sup>(15,16)</sup>; however, the prevalence and impact of FI in people living with a severe mental illness (SMI), including schizophrenia and other psychotic illnesses, are under-researched and potentially under-managed in clinical practice. A study from the USA of 111 people living with SMI found that the prevalence of FI was 71 %, considerably higher than the reported national prevalence of  $15 \, \%^{(17)}$ . Within the present study, those who were severely food insecure had significantly higher odds (OR 5.06) of psychiatric emergency room visits within the previous year compared with those who were food secure<sup>(17)</sup>.

People living with SMI often experience a lower standard of living, with poor functional outcomes, cognitive impairments, disability, and social and health inequalities<sup>(18,19)</sup>. This is frequently combined with socioeconomic barriers such as poverty, low income, unemployment, stigma, reduced independence and low self-efficacy<sup>(18–22)</sup>. It is therefore conceivable that FI may be highly prevalent in this population, further impacting on physical and mental health.

The high levels of physical morbidity and premature mortality among SMI populations are widely recognised, with a 15-year life expectancy reduction compared with people without SMI<sup>(23)</sup>. Recent studies documented the poor physical health of people with enduring SMI receiving clozapine<sup>(24)</sup> or longacting injectable (LAI) antipsychotics<sup>(25)</sup>.

The present study aimed to (i) assess the prevalence of FI in individuals with SMI receiving LAI antipsychotic medications and (ii) explore the relationship between FI and lifestyle factors in a sub-sample of people who were assessed for FI within the larger quality improvement project<sup>(25)</sup>.

#### Methods

NS British Journal of Nutrition

# Study design and setting

This cross-sectional study was conducted between October 2016 and December 2017 across three community mental health sites within the South Eastern Sydney Local Health District Mental Health Service. The present study was deemed a quality improvement or quality assurance project by the South Eastern Sydney Local Health District Human Research Ethics Committee (17/298 (LNR/17/POWH/580)).

## Participants

Participants were people experiencing SMI living in the community and receiving LAI treatment through the clinic service at one of the three community mental health sites. The present study aimed to include all people engaged with the LAI clinic; hence, there were no exclusion criteria within this cohort. Participants were invited to participate in the quality improvement project when attending the LAI clinic as part of routine care by clinicians within the clinic.

# Outcome measures

A series of measures was completed with participants facilitated by a clinician based on-site. Measures were completed in a private consulting room co-located with the LAI service. Sociodemographic and medication details. Participants' sociodemographic and medication details including sex, age, psychiatric diagnosis, psychotropic medication prescription and community treatment order status were obtained from medical records. Participants' country of origin (of birth) was categorised as (i) Australia, (ii) Asia or (iii) other. LAI antipsychotic prescriptions were converted to chlorpromazine equivalents, referred to as defined daily dose.

Anthropometry. Anthropometric data including height, weight, BMI, blood pressure and waist circumference were collected using standardised procedures. Participants were weighed without shoes and wearing light clothing on the OMRON HN-283 digital scale to the nearest 0.1 kg. Height was measured with shoes off, using a wall-mounted stadiometer to the nearest 0.1 cm. BMI was calculated as weight/height<sup>2</sup> with participants characterised as normal weight (18.5-24.9 kg/m<sup>2</sup>), overweight  $(25.0-29.9 \text{ kg/m}^2)$  and obese  $(\geq 30.0 \text{ kg/m}^2)$  as per WHO cut-offs<sup>(26)</sup>. Blood pressure was measured on the left arm in a seated position using an OMRON automatic sphygmomanometer. Waist circumference was measured horizontally at the navel at the end of expiration to the nearest 0.1 cm. Waist circumference was categorised as 'at risk' according to ethnic specific values from the International Diabetes Foundation criteria: Europids ( $\geq$ 80 cm for females and  $\geq$ 94 cm for males) and Asian people ( $\geq$ 80 cm for females and  $\geq$ 90 cm for males)<sup>(27)</sup>.

*Food security.* Participants completed the Radimer/Cornell Hunger and Food Insecurity questionnaire with assistance from a trained clinician. The Radimer/Cornell questionnaire has been validated for internal consistency, and construct and criterion-related validity, to assess hunger and FI at both a household and individual level<sup>(28)</sup>. The Radimer/Cornell questionnaire is a nine-question tool (children's section removed) consisting of food anxiety, food quality and food quantity components. Participants have three possible responses: (i) 'Not True', (ii) 'Sometimes True' or (iii) 'Often True'. Participants who answer either 'Sometimes True' or 'Often True' to any of the questions are considered food insecure.

*Dietary intake.* Diet was assessed through the use of a targeted ten-question, picture-guided, food intake questionnaire specifically developed to evaluate food patterns. The questionnaire evaluated intake of five 'healthy' and five 'unhealthy' food categories. Healthy food categories were fruits, vegetables, whole-grain foods, unsweetened dairy and alternatives and protein foods. Unhealthy food categories included unhealthy fats, sugary drinks, sweet foods, savoury discretionary foods and alcoholic beverages. Participants were asked to consider average frequency of intake over the last month and select from multiple choice responses: (i) less than once per week, (ii) multiple times per week, (iii) once per d and (iv) multiple times per d.

*Physical activity.* Previous 7-d physical activity was assessed using the International Physical Activity Questionnaire – Short Form<sup>(29)</sup>. The International Physical Activity Questionnaire – Short Form asks participants to recall time spent in vigorousand moderate-intensity physical activity, time spent walking

#### 472

and time spent sitting. A continuous indicator of physical activity at each intensity was calculated as a sum of weekly minutes per week. The percentage of clients achieving the WHO guidelines<sup>(30)</sup> of 150 min of moderate-to-vigorous physical activity (MVPA) per week was included as a categorical variable. The International Physical Activity Questionnaire has demonstrated reliability as a surveillance tool to assess the levels of physical activity in people with schizophrenia<sup>(31)</sup>.

*Smoking.* Nicotine dependence was measured using the Fagerström Test for Nicotine Dependence<sup>(32)</sup>, a six-item questionnaire. Scores of 1–2 indicate low dependence, 3–4 low to moderate dependence, 5–7 moderate dependence and 8+ high dependence.

# Statistical methods

Categorical descriptive statistics were calculated via crosstabulation and reported as numbers and percentages (sex, diagnosis, country of birth, LAI medication, community treatment order status, number of antipsychotic medications prescribed, additional mood stabiliser, antidepressant and benzodiazepine medications prescribed, BMI risk category, International Diabetes Foundation waist circumference risk category, dietary factors, smoking status and number of cigarettes smoked). Data distribution for continuous variables was assessed through histograms, and skewness and kurtosis values. Continuous descriptive statistics (age, LAI defined daily dose, weight, BMI, waist circumference, minutes in physical activity and sedentary time) were reported as means and standard deviations due to normal distributions.

 $\chi^2$  Tests were calculated to test for differences associated with the presence of food security and categorical variables: sex, diagnosis, prescribed LAI medication, community treatment order status, dietary factors (categorised as consumed at least once per d), smoking status and number of cigarettes smoked. Independent-samples t tests were run on food security status and continuous variables: age, weight, BMI, waist circumference, MVPA and sedentary time. Statistical significance was set at P < 0.05. For multiple comparisons of food security status against likely correlated dietary factors, a Bonferroni adjustment was implemented and statistical significance was modified to P < 0.006. For multiple comparisons on likely correlated physical activity factors, a Bonferroni adjustment was implemented and statistical significance was modified to P < 0.017. Binary logistic regression analyses were calculated adjusting for age and sex, and diagnosis and 'at risk' waist circumference (P < 0.1 for univariate model) to determine OR for lifestyle variables associated with FI. All statistical analyses were calculated using SPSS version 24.

#### Results

In total, 233 participants (45% of the total cohort receiving LAI) completed the food security questionnaire and other assessments (Table 1). Participants were able to decline to participate in any of the measures which resulted in lower sample sizes for certain measures. There were more people who completed the

survey receiving mood stabiliser medication compared with those who did not complete the survey. There were no differences between the two groups in demographic details or other clinical variables.

Of the participants who completed the food security survey,  $66\% (n \ 154)$  were males, and the median age was  $44.8 (sp \ 12.7)$  years. The majority of participants (63%) were born in Australia, and the remainder were born in an Asian country (18%) or other countries (22%) and had a primary diagnosis of schizophrenia (70%). Participants were prescribed a range of LAI antipsychotic medications, and  $34\% (n \ 79)$  were prescribed at least one additional oral antipsychotic. The frequency of additional oral psychotropic medications, other than antipsychotics, was as follows: mood stabiliser  $21\% (n \ 50)$ , antidepressant  $9\% (n \ 20)$  and benzodiazepine  $6\% (n \ 15)$ . Participants were mostly in the at-risk BMI categories, with 48% obese and 29% overweight. Eighty percentage had an at-risk waist circumference.

FI was prevalent in 45 % (*n* 108) of participants. There was no difference between food security status and sex, LAI medication or number of participants on a community treatment order (all  $\chi^2 < 1.0$ , all P > 0.30; Table 2). There was a trend to statistical significance for difference in diagnoses between food security status ( $\chi^2 = 5.8$ , all P = 0.056), with 48 and 43% of people with schizophrenia and schizoaffective disorder being food insecure, respectively, compared with 20% of people with bipolar affective disorder being food insecure. There was no difference in food security status and age, weight, BMI or waist circumference (all t < 1.6, all P > 0.11).

Participants who were food insecure were less likely to consume fruits (OR 0·42, 95 % CI 0·24, 0·74, P = 0.003), vegetables (OR 0·39, 95 % CI 0·22, 0·69, P = 0.001) or lean meat, poultry, fish and other protein-based foods (OR 0·45, 95 % CI 0·25, 0·83, P = 0.011) at least once per d (Table 3). People who were food insecure were more likely to smoke (OR 1·89, 95 % CI 1·08, 3·32, P = 0.026); however, within those who were smokers there was no difference between food security status for the categories of number of cigarettes smoked ( $\chi^2 = 0.7$ , P = 0.87). Food insecure participants also reported lower levels of MVPA (min) (OR 0·997, 95 % CI 0·993, 1·000, P = 0.044); however, there was no difference in sedentary time between food security status (t(220) = 0.2, P = 0.8).

# Discussion

The present study found a prevalence of FI in people with SMI receiving LAI medication of 45 %. Further, those reporting FI reported less healthful lifestyle behaviours. People with FI consumed less vegetables, fruits and lean meat, poultry, fish and other protein-based foods and were more likely to be smokers. These lifestyle behaviours are well-known risks for future non-communicable disease and all-cause mortality<sup>(33–35)</sup>, to which people with SMI are highly vulnerable<sup>(36)</sup>. The present study adds significantly to the evidence base for FI being a highly prevalent issue in this patient group. This is in line with findings from the limited number of studies that have to date explored the important question of FI in people with SMI<sup>(17)</sup>. The present study adds to this by additionally providing new insights into

473	https://doi.org/10.1017/S00071145200011
	91 Pul
	olished online by Cambridge University F
	ress

Table 1. Demographic and clinical details of people who participated in the survey and those who did not
(Numbers and percentages: mean values and standard deviations)

	Participated			Did	l not participa	ate	
	п		%	n		%	Statistical test
Demographic							
Age (years)							
Mean		44.8			45.7		t(514) = 0.85, P = 0.40
SD		12.7			12.4		
Male	154		66	176		62	$\chi^2 = 0.94, P = 0.33$
Country of birth							
Australia	145		62	167		60	$\chi^2 = 2.56, P = 0.28$
Asia	37		16	36		13	
Other	51		22	77		27	
Diagnosis and treatment Diagnosis							
Schizophrenia	156		69	205		75	$v^2 = 2.27$ , $P = 0.32$
Schizoaffective disorder	51		22	48		17	$\chi = 221$ , $Y = 0.02$
Bipolar affective disorder	20		9	22		8	
L AL medication	20		U			Ŭ	
Paliperidone	64		27	85		30	$v^2 = 7.38 P = 0.39$
Zuclopenthixol	47		20	64		23	$\chi^{2} = 1.000, 1 = 0.000$
Arininrazole	42		18	46		16	
Respiridone	33		14	41		14	
Flupenthixol	33		14	28		10	
Haloperidol	11		5	19		7	
Flunbenazine	2		1	0		,	
Olanzanine	1		1	0		0	
LAL defined daily dose (mg)				0		0	
Meen		1.1			1.1		#(510) = 0.2 P = 0.81
SD SD		0.5			0.5		i(010) = 0.2, T = 0.01
Participants with CTO	110	0.5	51	128	0.5	40	$^{2}-0.32$ $P-0.57$
Additional oral psychotropic medica	ations		51	150		45	χ = 0.32, 1 = 0.37
No oral antipsychotic	157		67	101		63	
	137		10	20		14	
Olarizapine	27		12	39		14	
Queilapine	21		12	30		13	
Aminularida	9		3	17		0	2 0 15 0 0 40
Amisupride	7		3	3		1	$\chi^2 = 8.15, P = 0.42$
Haloperidoi	0		0	1		1	
Paliperidone	2		1	3		1	
	2		1	0		0	
iviultiple oral antipsychotics	2		1	4		1	2 4 05 5 6 6 6 4
Mood stabiliser	50		21	41		14	$\chi^{2} = 4.35, P = 0.04^{*}$
Antidepressant	20		9	34		12	$\chi^{2} = 1.57, P = 0.21$
Benzodiazepine	15		6	18		6	$\chi^{2} = 0.00, P = 0.96$

LAI, long-acting injectable medication; CTO, community treatment order.

\* *P* < 0.05.

associations of FI with other factors including BMI, cigarette smoking and physical activity.

The prevalence of FI in people with SMI receiving LAI medication appears significantly higher than both the national rates in the general Australian population (approximately 5 %)<sup>(5)</sup>, rates in the Australian population using the Radimer/Cornell Hunger and Food Insecurity questionnaire  $(13 \%)^{(3,4)}$  and worldwide rates (11 % undernourished, 10 % severe FI)<sup>(2)</sup>. Several factors may contribute to the high prevalence of FI in SMI. First, financial constraints are a common barrier for people with persistent SMI, due to high rates of unemployment or partial employment requiring government support<sup>(37,38)</sup>. Second, people with SMI often have poorer culinary skills<sup>(39)</sup> and may have limited food storage and preparation options<sup>(40)</sup>. Third, more than 50 % of people with SMI do not drive and therefore rely on public transport or other family members or carers to access food stores<sup>(41)</sup>. Fourth, symptoms and characteristics of mental illness, such as social anxiety and persecutory ideas, can lead to people with SMI avoiding supermarkets<sup>(42)</sup>. In addition, we do not know whether people receiving LAI treatment are representative of other SMI cohorts and may in fact have higher rates of disadvantage, given this cohort has the highest rate of involuntary treatment and is often poorly engaged with health services.

It is well documented that people with SMI have less healthy dietary intake compared with those without mental illness, and they may fall short of national targets for healthy recommended dietary intake<sup>(43)</sup>. It is known that dietary interventions can improve physical health in people with SMI<sup>(44)</sup>. However, assessing for and providing strategies to manage FI may be a necessary addition to routine clinical care for this population. Future studies should evaluate the effectiveness of interventions to improve food security in people with SMI and FI, and its subsequent effect on nutritional intake and diet quality. The high prevalence of smokers in the food insecure group is a possible reflection of

474

# S. B. Teasdale et al.

%

Statistical test

#### Table 2. Demographic and clinical details of participants (Numbers and percentages; mean values and standard deviations)

Food secure (n 129) Food insecure (n 104) п % п

Mean45.643.7 $t(231) = 1.1, P = 0.26$ so13.212.1Male82647269 $\chi^2 = 0.83, P = 0.36$ Country of birthAustralia84656159Australia20161716 $\chi^2 = 1.24, P = 0.54$ Other25192625Diagnosis and treatmentDiagnosis5Schizophrenia84657875Schizophrenia84657875Schizophrenia84657875Schizophrenia84657875Schizophrenia84657875Schizophrenia84657875Schizophrenia84657875Schizophrenia84657875Schizophrenia84657875Schizophrenia25192221Zucopenthixol25192221Aripiprazole20152221Aripiprazole201514Haloperidol655Fupentaixol18141515Haloperidol6555Paticipants with CTO62485755Articipants with CTO62485755Articipants with CTO62485755Articipante1291514
Index       Ito 3       Ito 3       Ito 3       Ito 4       Ito 4 <thito 4<="" th=""> <thito 4<="" th=""> <thi< td=""></thi<></thito></thito>
Male       82       64       72       69 $\chi^2 = 0.83, P = 0.36$ Country of birth       Australia       84       65       61       59         Australia       20       16       17       16 $\chi^2 = 0.83, P = 0.36$ Other       25       19       26       25         Diagnosis and treatment       25       19       26       25         Diagnosis and treatment       84       65       78       75         Schizophrenia       84       65       78       75         Paliperidone       16       13       4       4         L'I medication (n 232)       Paliperidone       16       12       17       16 $\chi^2 = 7.33, P = 0.40$ Flupenthixol       18       14       15       15       15         Haloperidol       6       5       5       5       2 = 1.05, P = 0.31
Number of the constraint of the co
Australia       84       65       61       59         Asia       20       16       17       16 $\chi^2 = 1.24, P = 0.54$ Other       25       19       26       25         Diagnosis       Schizophrenia       84       65       78       75         Schizopaffective disorder       29       22       22       21 $\chi^2 = 5.77, P = 0.06$ Bipolar affective disorder       16       13       4       4         LAI medication (n 232)       Paliperidone       42       33       22       21         Aripiprazole       20       15       22       21         Aripiprazole       20       15       22       21         Aripiprazole       20       15       22       21         Respiritone       16       12       17       16 $\chi^2 = 7.33, P = 0.40$ Flupenthixol       18       14       15       15         Haloperidol       6       5       5       5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotic       89       69       68       66       0lanzapin
Asia       20       16       17       16 $\chi^2 = 1.24, P = 0.54$ Other       25       19       26       25         Diagnosis       Schizophrenia       84       65       78       75         Paliperidon       42       33       22       21         Aripiprazole       20       15       22       21         Aripiprazole       20       15       22       21         Respiridone       16       12       17       16 $\chi^2 = 7.33, P = 0.40$ Fluppentixol       18       14       15       15         Haloperidol       6       5       5       5         Participants with CTO </td
Add       20       10       11       10 $\chi = 1/24$ , $f = 0.04$ Other       25       19       26       25         Diagnosis       Schizophrenia       84       65       78       75         Paliperidone       16       13       4       4         Lul medication (n 232)       22       21       21       22       21         Paliperidone       16       12       17       16 $\chi^2 = 7.33$ , $P = 0.40$ 16         Fluppentaine       2       2       0       0       1       1.1       1.1       1.1       1.1       1.1       1.1       1.1       1.1       1.1       1.1       1.1       1.1
Diagnosis and treatment       LS       LS       LS       LS         Diagnosis       Schizophrenia       84       65       78       75         Schizophrenia       16       13       4       4         LAI medication (n 232)       Paliperidone       42       33       22       21         Aripiprazole       20       15       22       21       22       21         Aripiprazole       20       15       22       21       22       21         Respiridone       16       12       17       16 $\chi^2$ =7.33, P=0.40         Flupentixol       18       14       15       15       15         Haloperidol       6       5       5       5       5         Fluphenazine       2       2       0       0       1       1         LAI defined daily dose (mg) (n 231)       Mean       1.1       1.1       <
Diagnosis       Schizophrenia       84       65       78       75         Schizophrenia       16       13       4       4         LAI medication (n 232)       Paliperidone       42       33       22       21         Arapiprazole       20       15       22       21         Arapiprazole       20       15       22       21         Respiridone       16       12       17       16 $\chi^2$ =7·33, P=0·40         Flupenthixol       18       14       15       5       5         Fluphenazine       2       2       0       0       0       1       1         LAI defined daily dose (mg) (n 231)       Mean       1·1       1·1       1/1       1(230)=0·9, P=0·38       55 $\chi^2$ =1·05, P=0·31         Additional oral psychotropic medications       Antipsychotic       80       0·5       0·5       2/2       1·05, P=0·31         Additional oral psychotropic medications       Antipsychotic       89
Schizophrenia       84       65       78       75         Schizophrenia       84       65       78       75         Schizophrenia       84       65       78       75         Schizophrenia       16       13       4       4         LAI medication (n 232)       Paliperidone       42       33       22       21         Paliperidone       42       13       4       4         LAI medication (n 232)       Paliperidone       42       23       22       21         Aripiprazole       20       15       22       21         Aripiprazole       20       15       22       21         Respiridone       16       12       17       16 $\chi^2 = 7.33, P = 0.40$ Fluphenazine       2       2       0       0       1       1         Haloperidol       6       5       5       5       5       5         Fluphenazine       2       2       0       0       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1
Schizopinetia64637673Schizopinetia161344LAI medication (n 232)1344Paliperidone42332221Zuclopenthixol25192221Aripiprazole20152221Respiridone16121716 $\chi^2 = 7.33, P = 0.40$ Flupenthixol18141515Haloperidol6555Fluphenazine2200Olanzapine0011LAI defined daily dose (mg) (n 231)1.11.1t(230) = 0.9, P = 0.38SD0.50.50.50.5Participants with CTO62485755Artipsychotic89696866Olanzapine1291514Amisulpride6411Clozapine2200Quetapine1291514Paliperidone2200Quetapine1291514Lurasidone2200Multiple oral antipsychotics111Multiple oral antipsychotics111Multiple oral antipsychotics111Multiple oral antipsychotics111Multiple oral antipsychotics111Mu
Solution232221 $\chi = 5.77, T = 0.00$ Bipolar affective disorder161344LAI medication (n 232)132221Paliperidone42332221Aripiprazole20152221Aripiprazole20152221Respiridone16121716 $\chi^2 = 7.33, P = 0.40$ Flupenthixol18141515Haloperidol6555Flupenazine2200Olanzapine0011LAI defined daily dose (mg) (n 231)1.11.11.1Mean1.11.11.1t(230) = 0.9, P = 0.38SD0.50.50.50.5Participants with CTO62485755Additional oral psychotropic medications344Antipsychotic89696866Olanzapine1291514Amisulpride6411Clozapine5444Paliperidone2200Quetiapine1291514Lurasidone2200Multiple oral antipsychotics1111Multiple oral antipsychotics1111
Lal medication (n 232)1344Paliperidone42332221Zuclopenthixol25192221Aripiprazole20152221Respiridone16121716 $\chi^2 = 7.33, P = 0.40$ Flupenthixol18141515Haloperidol6555Flupenthixol18141515Haloperidol6555Fluphenazine2200Olanzapine0011LAI defined daily dose (mg) (n 231)0.50.50.5Mean1.11.11.1t(230) = 0.9, P = 0.38sp0.50.50.50.5Participants with CTO62485755Additional oral psychotic89696866Olanzapine1291514Amisulpride6411Clozapine5444Paliperidone2200Quetiapine1291514Lurasidone2200Multiple oral antipsychotics111Multiple oral antipsychotics111
Paliperidone       42       33       22       21         Aripiprazole       20       15       22       21         Aripiprazole       20       15       22       21         Respiridone       16       12       17       16 $\chi^2$ =7·33, P=0·40         Flupenthixol       18       14       15       15         Haloperidol       6       5       5       5         Fluphenazine       2       2       0       0         Olanzapine       0       0       1       1         LAI defined daily dose (mg) (n 231)       Mean       1·1       1·1       t(230) = 0·9, P = 0·38         Mean       0·5       0·5       0·5       5 $\chi^2$ =1·05, P = 0·31         Additional oral psychotropic medications       0·5       0·5 $\chi^2$ =1·05, P = 0·31         Additional oral psychotic       89       69       68       66         Olanzapine       12       9       15       14         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2$ =8·57
Pathemotion42332221Zuclopenthixol25192221Aripiprazole20152221Respiridone16121716 $\chi^2 = 7.33, P = 0.40$ Flupenthixol18141515Haloperidol6555Fluphenazine2200Olanzapine0011LAI defined daily dose (mg) (n 231)1.11.11.1Mean1.11.11.1t(230) = 0.9, P = 0.38so0.50.50.5Participants with CTO624857Additional oral psychotic89696866Olanzapine1291514Amisulpride6411Clozapine5444Paliperidone2200Quetiapine1291514Lurasidone2200Multiple oral antipsychotics111Quetiapine1291514Lurasidone2200Multiple oral antipsychotics111Multiple oral antipsychotics111Multiple oral antipsychotics111Multiple oral antipsychotics111Multiple oral antipsychotics111Multiple oral ant
Aripiprazole       20       15       22       21         Aripiprazole       20       15       22       21         Respiridone       16       12       17       16 $\chi^2 = 7.33, P = 0.40$ Flupenthixol       18       14       15       15         Haloperidol       6       5       5       5         Fluphenazine       2       2       0       0         Olazapine       0       0       1       1         LAI defined daily dose (mg) (n 231)       Mean       1.1       1.1       t/(230) = 0.9, P = 0.38         SD       0.5       0.5       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medications       0.5       0.5       0.5         Antipsychotic       89       69       68       66         Olazapine       12       9       15       14         Amisulpride       6       4       1       1         Addiptione       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14<
Alipprazile       20       15       22       21         Respiridone       16       12       17       16 $\chi^2 = 7.33, P = 0.40$ Flupenthixol       18       14       15       15         Haloperidol       6       5       5       5         Fluphenazine       2       2       0       0         Olanzapine       0       0       1       1         LAI defined daily dose (mg) (n 231)       Mean       1.1       1.1       1.1       t(230) = 0.9, P = 0.38         SD       0.5       0.5       0.5       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medications       12       9       15       14       14         Amisulpride       6       4       1       1       1       1         Clozapine       5       4       4       4       4       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14       14       14       14       14       14       14       14       14       14
Hespinione       10       12       17       16 $\chi^2$ = 7-33, P = 0-40         Flupenthixol       18       14       15       15         Haloperidol       6       5       5       5         Fluphenazine       2       2       0       0         Olanzapine       0       0       1       1         LAI defined daily dose (mg) (n 231)       Mean       1.1       1.1       t/(230) = 0.9, P = 0.38         SD       0.5       0.5       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2$ = 1.05, P = 0.31         Additional oral psychotropic medications       Antipsychotic       89       69       68       66         Olanzapine       12       9       15       14         Armisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2$ = 8.57, P = 0.29         Quetiapine       12       9       15       14       1         Lurasidone       2       2       0       0       0         Multiple oral ant
Hupertinizor       18       14       15       15         Haloperidol       6       5       5       5         Fluphenazine       2       2       0       0         Olanzapine       0       0       1       1         LAI defined daily dose (mg) (n 231)       1.1       1.1       1.1       t(230) = 0.9, P = 0.38         SD       0.5       0.5       0.5       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medications       Antipsychotic       89       69       68       66         Olanzapine       12       9       15       14       4         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14       1         Lurasidone       2       2       0       0       0         Multiple oral antipsychotics       1       1       1       1       1
Haloperidol       6       5       5       5         Fluphenazine       2       2       0       0         Olanzapine       0       0       1       1         LAI defined daily dose (mg) (n 231)       Mean       1.1       1.1 $t(230) = 0.9, P = 0.38$ SD       0.5       0.5       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medications       Antipsychotic       89       69       68       66         Olanzapine       12       9       15       14       4         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14       1         Lurasidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Multiple oral antipsychotics       1       1       1       1       1
Huppenazine       2       2       0       0         Olanzapine       0       0       1       1         LAI defined daily dose (mg) (n 231)       0.5       0.5       0.5         Mean       1.1       1.1       t(230) = 0.9, P = 0.38         so       0.5       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medications       Antipsychotic       89       69       68       66         Olanzapine       12       9       15       14         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14       1         Lurasidone       2       2       0       0       0         Multiple oral antipsychotics       1       1       1       1       1
Olanzapine       0       0       1       1         LAI defined daily dose (mg) (n 231)       Mean       1.1       1.1 $t(230) = 0.9, P = 0.38$ SD       0.5       0.5       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medications       Antipsychotic       89       69       68       66         Olanzapine       12       9       15       14       4         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14       1         Lurasidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Multiple oral antipsychotics       1       1       1       1       1
LAI defined daily dose (mg) (n 231)       1.1       1.1       1.1       t(230) = 0.9, P = 0.38         SD       0.5       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medications       Antipsychotic       89       69       68       66         Not-oral antipsychotic       89       69       68       66         Olanzapine       12       9       15       14         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14       14         Lurasidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14       15         Lurasidone       2       2       0       0       0         Multiple oral antipsychotics       1       1       1       1       1
Mean       1.1       1.1       1.1 $t(230) = 0.9, P = 0.38$ sp       0.5       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medications       Antipsychotic       89       69       68       66         Not-oral antipsychotic       89       69       68       66         Olanzapine       12       9       15       14         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14       14         Lurasidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Multiple oral antipsychotics       1       1       1       1       1
SD       0.5       0.5         Participants with CTO       62       48       57       55 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medications       Antipsychotic       7       55 $\chi^2 = 1.05, P = 0.31$ Additional oral antipsychotic       89       69       68       66         Olanzapine       12       9       15       14         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14       14       14         Lurasidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ 0         Multiple oral antipsychotics       1       1       1       1       1       1       1
Participants with CTO62485755 $\chi^2 = 1.05, P = 0.31$ Additional oral psychotropic medicationsAntipsychotic89696866Not-oral antipsychotic89696866Olanzapine1291514Amisulpride6411Clozapine5444Paliperidone2200 $\chi^2 = 8.57, P = 0.29$ Quetiapine1291514Lurasidone2200Multiple oral antipsychotics111Multiple oral antipsychotics1000
Additional oral psychotropic medicationsAntipsychotic89696866Not-oral antipsychotic8991514Amisulpride6411Clozapine5444Paliperidone2200 $\chi^2$ =8.57, P=0.29Quetiapine1291514Lurasidone22000Multiple oral antipsychotics1111
Antipsychotic       89       69       68       66         Not-oral antipsychotic       89       9       15       14         Olanzapine       12       9       15       14         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14         Lurasidone       2       2       0       0         Multiple oral antipsychotics       1       1       1       1
Not-oral antipsychotic       89       69       68       66         Olanzapine       12       9       15       14         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14         Lurasidone       2       2       0       0         Multiple oral antipsychotics       1       1       1       1
Olanzapine       12       9       15       14         Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14         Lurasidone       2       2       0       0         Multiple oral antipsychotics       1       1       1
Amisulpride       6       4       1       1         Clozapine       5       4       4       4         Paliperidone       2       2       0       0 $\chi^2 = 8.57, P = 0.29$ Quetiapine       12       9       15       14         Lurasidone       2       2       0       0         Multiple oral antipsychotics       1       1       1
Clozapine5444Paliperidone2200 $\chi^2 = 8.57, P = 0.29$ Quetiapine1291514Lurasidone2200Multiple oral antipsychotics111Multiple oral antipsychotics1000
Paliperidone2200 $\chi^2 = 8.57, P = 0.29$ Quetiapine1291514Lurasidone2200Multiple oral antipsychotics111Multiple oral antipsychotics1000
Quetiapine1291514Lurasidone2200Multiple oral antipsychotics111Multiple oral antipsychotics1000
Lurasidone 2 2 0 0 Multiple oral antipsychotics 1 1 1 1 Multiple oral antipsychotics 2 0 0 0
Multiple oral antipsychotics 1 1 1 1 1
Mood stabiliser $27$ $21$ $23$ $22$ $\chi^2 = 0.05, P = 0.83$
Antidepressant 12 9 8 8 $\chi^2 = 0.19, P = 0.66$
Benzodiazepine 8 6 7 7 $\chi^2 = 0.03, P = 0.87$
Anthropometry
Weight (kg) ( $n 217$ ) 92.2 30.7 87.2 23.9 $t(221) = 1.3$ , $P = 0.19$
BMI $(kg/m^2)$ (n 208) 31.2 8.8 29.4 7.4 $t(207) = 1.6, P = 0.11$
BMI category (n 208)
Underweight 1 1 1 1
Healthy 18 16 29 30
Overweight 34 30 26 27 $\chi^2 = 7.9, P = 0.16$
Obese (class I) 34 30 19 20
Obese (class II) 12 11 13 13
Obese (class III)         13         12         8         9
Waist circumference (cm) (n 222)         106·2         18·2         103·3         18·1         t(221) = 1·2, P = 0·24
Waist circumference risk category (n 222)
At metabolic risk 17 14 27 26 $\chi^2 = 4.9, P = 0.02$
Not at metabolic risk 102 86 76 74

LAI, long-acting injectable medication; CTO, community treatment order. P < 0.05.

the significant costs associated with buying cigarettes and tobacco products. An Australian study of people with mental illness receiving a disability support pension found that smoking on average forty cigarettes per d equates to 37% of their pension<sup>(45)</sup>. Given the high rates of smoking found in this sample (63%), similar to the percentage of smokers among people with SMI more generally (approximately 66%)<sup>(46)</sup>, further research

and development of targeted clinical interventions are suggested. Prospective studies that monitor monetary spending over time, particularly focussing on smoking and other substances, and the effect on food security are needed. Lower levels of physical activity for food insecure people are a consistent finding<sup>(47</sup>); however, the potential relationship between FI and MVPA is unclear. A number of factors which correlate with lower

**W** British Journal of Nutrition

#### Food insecurity in severe mental illness

 Table 3. Comparison of lifestyle characteristics by food security status\*

(Numbers and percentages; mean values and standard deviations; odds ratios and 95 % confidence intervals)

	Food secure		Food insecure		cure		Binary logistic regression			
	n		%	n		%	$\chi^2/t$ test‡	OR	95 % CI	Р
Dietary intake (consumed at least once per d, n 220)										
Vegetables	60		50	25		25	$\chi^2 = 13.6, P < 0.001^{+}$	0.39	0.22, 0.69	0.001†
Fruits	58		48	25		25	$\chi^2 = 11.9, P = 0.001^{+}$	0.42	0.24, 0.74	0.003†
Whole grains	54		44	43		43	$\chi^2 = 0.8, P = 0.77$			
Plain dairy and dairy alternatives	84		69	69		70	$\chi^2 = 0.5, P = 0.82$			
Lean meat, poultry, fish and other protein-based foods	55		45	25		25	$\chi^2 = 9.3, P = 0.002$	0.45	0.25, 0.83	0.011*
Sugary drinks	45		37	46		47	$\chi^2 = 2.1, P = 0.15$			
Savoury discretionary foods	16		13	18		18	$\chi^2 = 1.0, P = 0.31$			
Sweet discretionary foods	25		21	23		23	$\chi^2 = 2.1, P = 0.34$			
Physical activity (min/d) (n 222)										
Sedentary time										
Mean		433			440		t(220) = 0.2, P = 0.81			
SD		211			220					
Walking										
Mean		311			226		t(200) = 1.7, P = 0.09			
SD		464			266					
Moderate and vigorous physical activity										
Mean		59			22		$t(173) = 2.4, P = 0.017^*$	0.997	0.993, 1.000	0.044*
SD		152			66					
Currrent smoker (n 219)	69		58	71		72	$\chi^2 = 4.8, P = 0.029^*$	1.89	1.08, 3.32	0.026*
Nicotine dependence (within smoking cohort, n 145)							<i>x</i>		,	
High	14		21	12		18				
Moderate	25		36	32		48	$\chi^2 = 2.4, P = 0.49$			
Low-moderate	18		26	16		24				
Low	12		17	7		10				

\* P < 0.05

NS British Journal of Nutrition

† *P* < 0.01.

+ χ<sup>2</sup> Statistical significance was adjusted to P < 0.006 for dietary components, and independent-samples *t* test statistical significance was adjusted to P < 0.017 for physical activity factors. Binary logistic regression analyses were adjusted for age, sex, diagnosis and 'at risk waist circumference' to determine OR for people who were food insecure.

physical activity in people with SMI, such as low socioeconomic status, physical co-morbidities and smoking status, appear to correlate with FI in the general population, questioning a causative relationship<sup>(48,49)</sup>. Prospective studies of FI and its relationship to MVPA levels in people with SMI are needed to help understand this relationship.

#### Limitations

The limitations of the present study are as follows. First, a number of subjective measures were utilised in the present study potentially reducing the accuracy when compared with objective measures. The food intake questionnaire has not yet been validated in SMI population. Given the high prevalence of cognitive and memory deficits along people with SMI, a simplified, picture-guided tool was developed to give an overall indication of frequency of categorised food choices. Second, the crosssectional design prevents causal conclusions being made and, however, does provide evidence to support future prospective observational and intervention studies. Third, there is potential for selection bias given that only 45 % of the total available cohort completed the survey. However, comparisons of available demographic and clinical data revealed minimal differences between those who completed the survey and those did not, indicating that there was otherwise no evidence to suggest any systematic bias. No obvious explanation was identified for the difference in mood stabiliser prescription rates between the two groups. Fourth, the questionnaire utilised in the study did not distinguish whether the FI identified in the present study was acute or chronic. Lastly, the relationship between socioeconomic status and FI was not explored.

Despite these limitations, the present study provided insight into understanding the prevalence of FI and its relationship to other health behaviours in this highly vulnerable group. The following gaps remain: (i) validation studies are required of both dietary assessment methods and food security measures specifically for people with SMI to determine optimal assessment methods, (ii) future studies should explore the relationship of additional demographic and treatment elements with food security status including socioeconomic status, and duration of illness and exposure to antipsychotic medication, and alcohol and substance use and (iii) prospective studies are needed to observe participants' budgetary spending in relation to food, housing, smoking and substance use and other factors to identify impacts on food security. Given the increasing number of dietitians working in mental health services, evaluating food security status could become an important component of routine care to include in initial assessments in order to guide optimal interventions.

#### Conclusion

FI is highly prevalent in people with SMI receiving LAI antipsychotic medications. People who were food insecure engaged in less healthy lifestyle behaviours, increasing the risk of future non-communicable diseases. Future studies which explore causal pathways will help to target interventions for FI for mental health teams. S. B. Teasdale et al.

# Acknowledgements

The authors acknowledge clinicians within the Keeping the Body in Mind program, South Eastern Sydney Local Health District for their assistance with data collection.

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

All authors were involved in the design of the study. S. B. T. led manuscript preparation with input from all co-authors. All authors approved the final version of the manuscript.

The authors declare that there are no conflicts of interest.

#### References

- 1. Food and Agriculture Organization (2010) *The Right to Adequate Food.* Geneva: United Nations.
- FAO, IFAD, UNICEF, et al. (2018) The State of Food Security and Nutrition in the World 2018: Building Climate Resilience for Food Security and Nutrition. Rome: FAO.
- Russell J, Flood V, Yeatman H, *et al.* (2014) Prevalence and risk factors of food insecurity among a cohort of older Australians. *J Nutr Health Aging* 18, 3–8.
- Russell JC, Flood VM, Yeatman H, et al. (2016) Food insecurity and poor diet quality are associated with reduced quality of life in older adults. Nutr Diet 73, 50–58.
- Australian Bureau of Statistics (ABS) (2015) National Health Survey 2014–2015. Canberra: ABS.
- Coleman-Jensen A, Gregory C & Singh A (2014) Household Food Security in the United States in 2013, ERR-173. Washington, DC: Economic Research Service, U.S. Department of Agriculture.
- Booth S & Smith A (2001) Food security and poverty in Australia-challenges for dietitians. *Aust J Nutr Diet* 58, 150–156.
- Rosier K (2012) Food insecurity in Australia: what is it, who experiences it and how can child and family services support families experiencing it? *J Home Econ Inst Aust* 19, 25–30.
- Radimer KL (2006) Measurement of household food security in the USA and other industrialised countries. *Public Health Nutr* 5, 859–864.
- Lindberg R, Lawrence M, Gold L, *et al.* (2015) Food insecurity in Australia: implications for general practitioners. *Aust Fam Physician* 44, 859–862.
- 11. Ramsey R, Giskes K, Turrell G, *et al.* (2011) Food insecurity among Australian children: potential determinants, health and developmental consequences. *J Child Health Care* **15**, 401–416.
- Kleve S, Davidson ZE, Gearon E, *et al.* (2017) Are low-to-middleincome households experiencing food insecurity in Victoria, Australia? An examination of the Victorian Population Health Survey, 2006–2009. *Aust J Prim Health* 23, 249–256.
- Hanson KL & Connor LM (2014) Food insecurity and dietary quality in US adults and children: a systematic review. *Am J Clin Nutr* **100**, 684–692.
- Johnson CM, Sharkey JR, Lackey MJ, *et al.* (2018) Relationship of food insecurity to women's dietary outcomes: a systematic review. *Nutr Rev* 76, 910–928.
- Davison KM, Marshall-Fabien GL & Tecson A (2015) Association of moderate and severe food insecurity with suicidal ideation in adults: national survey data from three Canadian provinces. *Soc Psychiatry Psychiatr Epidemiol* **50**, 963–972.
- Siefert K, Heflin CM, Corcoran ME, *et al.* (2004) Food insufficiency and physical and mental health in a longitudinal survey of welfare recipients. *J Health Social Behav* 45, 171–186.

- Mangurian C, Sreshta N & Seligman H (2013) Food insecurity among adults with severe mental illness. *Psychiatr Serv* 64, 931–932.
- 18. Morgan VA, McGrath JJ, Jablensky A, *et al.* (2014) Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. *Psychol Med* **44**, 2163–2176.
- Scott EM, Hermens DF, White D, *et al.* (2015) Body mass, cardiovascular risk and metabolic characteristics of young persons presenting for mental healthcare in Sydney, Australia. *BMJ Open* 5, e007066.
- Steele L, Dewa C & Lee K (2007) Socioeconomic status and selfreported barriers to mental health service use. *Can J Psychiatry* 52, 201–206.
- Enticott JC, Meadows GN, Shawyer F, et al. (2015) Mental disorders and distress: associations with demographics, remoteness and socioeconomic deprivation of area of residence across Australia. Aust NZ J Psychiatry 50, 1169–1179.
- Olesen SC, Butterworth P, Leach LS, *et al.* (2013) Mental health affects future employment as job loss affects mental health: findings from a longitudinal population study. *BMC Psychiatry* 13, 144.
- Lawrence D, Hancock KJ & Kisely S (2013) The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. *BMJ* 346, f2539.
- 24. Lappin JM, Wijaya M, Watkins A, *et al.* (2018) Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients. *Schizophr Res* **199**, 367–373.
- Morell R, Curtis J, Watkins A, *et al.* (2019) Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication. *Psychiatry Res* 282, 112606.
- World Health Organization (WHO) (1995) *Physical Status: The* Use of and Interpretation of Anthropometry, Report of a WHO Expert Committee. Geneva: WHO.
- Alberti KGMM, Zimmet P & Shaw J (2006) Metabolic syndrome

   a new world-wide definition. A consensus statement from the
   international diabetes federation. *Diabet Med* 23, 469–480.
- Kendall A, Olson CM & Frongillo EA Jr (1995) Validation of the Radimer/Cornell measures of hunger and food insecurity. J Nutr 125, 2793–2801.
- Craig CL, Marshall AL, Sjostrom M, *et al.* (2003) International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* **35**, 1381–1395.
- World Health Organization (WHO) (2010) Global Recommendations on Physical Activity for Health. Geneva: WHO Press.
- Faulkner G, Cohn T & Remington G (2006) Validation of a physical activity assessment tool for individuals with schizophrenia. *Schizophr Res* 82, 225–231.
- Heatherton TF, Kozlowski LT & Frecker RC (1991) The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. *BrJ Addict* 86, 1119–1127.
- 33. Banks E, Joshy G, Weber MF, et al. (2015) Tobacco smoking and all-cause mortality in a large Australian cohort study: findings from a mature epidemic with current low smoking prevalence. BMC Med 13, 38.
- 34. Gebel K, Ding D, Chey T, *et al.* (2015) Effect of moderate to vigorous physical activity on all-cause mortality in middle-aged and older Australians. *JAMA Int Med* **175**, 970–977.
- 35. Wang X, Ouyang Y, Liu J, *et al.* (2014) Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. *BMJ* **349**, g4490.
- Thornicroft G (2011) Physical health disparities and mental illness: the scandal of premature mortality. *Br J Psychiatry* 199, 441–442.

# 476

- Marwaha S & Johnson S (2004) Schizophrenia and employment. Soc Psychiatry Psychiatr Epidemiol 39, 337–349.
- Marson DC, Savage R & Phillips J (2005) Financial capacity in persons with schizophrenia and serious mental illness: clinical and research ethics aspects. *Schizophr Bull* 32, 81–91.
- Semkovska M, Stip E, Godbout L, *et al.* (2002) Behavioral disorganization in schizophrenia during a daily activity: the kitchen behavioral scoring scale. *Brain Cogn* 48, 546–553.
- Rog DJ (2004) The evidence on supported housing. *Psychiatr Rehabil J* 27, 334.
- Palmer BW, Heaton RK, Gladsjo JA, *et al.* (2002) Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. *Schizophr Res* 55, 205–215.
- 42. Pallanti S, Quercioli L & Hollander E (2004) Social anxiety in outpatients with schizophrenia: a relevant cause of disability. *Am J Psychiatry* **161**, 53–58.
- Teasdale SB, Ward PB, Samaras K, *et al.* (2019) Dietary intake of people with severe mental illness: systematic review and metaanalysis. *Br J Psychiatry* 214, 251–259.

- 44. Teasdale SB, Ward PB, Rosenbaum S, *et al.* (2017) Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. *Br J Psychiatry* **210**, 110–118.
- Lawn S (2001) Australians with mental illness who smoke. Br J Psychiatry 178, 85.
- Morgan VA, Waterreus A, Jablensky A, *et al.* (2012) People living with psychotic illness in 2010: the second Australian national survey of psychosis. *Aust N Z J Psychiatry* 46, 735–752.
- 47. To QG, Frongillo EA, Gallegos D, *et al.* (2014) Household food insecurity is associated with less physical activity among children and adults in the U.S. population. *J Nutr* **144**, 1797–1802.
- Bauman AE, Reis RS, Sallis JF, *et al.* (2012) Correlates of physical activity: why are some people physically active and others not? *Lancet* 380, 258–271.
- Vancampfort D, Knapen J, Probst M, *et al.* (2012) A systematic review of correlates of physical activity in patients with schizophrenia. *Acta Psychiatr Scand* **125**, 352–362.

477

https://doi.org/10.1017/S0007114520001191 Published online by Cambridge University Press